Featured News

The CeliacShield Study is being conducted to assess the investigational drug latiglutenase and its ability to protect the small intestine of celiac disease patients from gluten exposure.

We are thrilled to once again be an Official Charity Partner of the largest marathon in the world, the 2019 TCS New York City Marathon.

To ensure our community gets the representation it deserves, we are delighted to announce that we have retained Ben Nicholson, a consultant based in Washington, DC, to provide legislative, policy, and advocacy services for the Foundation.

Results from a new study suggest that cell immunity in the bowel is irreversibly altered by celiac disease. Early diagnosis and treatment of celiac disease may be able to save some of these beneficial cells and prevent additional permanent damage.

Love is in the air, and there is nothing as sweet as finding gluten-free candy options for Valentine's Day!

If you have celiac disease and currently have kidney stones, or have had kidney stones in the past, you may be eligible for a new clinical research study!

The Celiac Disease Foundation is pleased to announce Dr. Schär's continued support of the Foundation and dedication to the gluten-free community.

We need YOUR help to achieve our mission of accelerating diagnosis, treatments, and a cure for celiac disease! Creating a Facebook fundraising page is a quick and easy way to raise funds and awareness.

The Foundation signs comment letter to CMS on proposed rule: Modernizing Part D and Medicare Advantage to Lower Drug Prices and Reduce Out-of-Pocket Expenses.

Increased consumption of a bacterial enzyme that is a common additive in processed foods might be related to the increased incidence of celiac disease.